Drug intelligence / Profile preview

KHK4577

Development stage: Phase 2
Lead developer: Kyowa Kirin
Modality: Small Molecules
Administration: Oral

Overview

KHK4577 is an orally active small molecule antagonist of the histamine H4 receptor (H4R) developed by Kyowa Kirin for the treatment of atopic dermatitis. The histamine H4 receptor is a G protein-coupled receptor primarily expressed on hematopoietic cells, including mast cells, eosinophils, dendritic cells, and T cells, where it mediates chemotaxis and the production of pro-inflammatory cytokines. By selectively antagonizing H4R, KHK4577 aims to reduce the pruritus (itching) and underlying skin inflammation associated with atopic dermatitis. The compound has been evaluated in Phase 2 clinical trials in Japan to assess its efficacy and safety in patients with moderate-to-severe disease.

Other names: KHK4577KHK-4577KHK 4577

Targets

HRH4 (Histamine H4 receptor)

Beyond the preview

Go deeper on KHK4577.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KHK4577.

Explore the full profile